The Indian banking regulator, however, left cypto currency out of the list. Credit registry, credit information, Initial Coin Offering (ICO) and chain marketing have also been kept out of the sandbox.
This pharma player has risks loaded up as margins took a hit. But that’s not stopping it from playing to its strengths
The counter warrants investor attention on account of the double-digit earnings growth visibility in the medium term
According to an announcement made by Torrent to the US Food and Drug Administration on January 22, the impurity detected in the API is N-nitrosodiethylamine (NDEA).
There are around 7,000 active pharmaceutical ingredient manufacturers in China which provide raw material to 80 percent of drug makers in India.
Any disruption in the supply chain induced by artificial scarcity, production cuts, or bad bilateral relations with China could impact domestic drug-makers.
A spotlight on Dr. Reddy's Laboratories (DRL), a big relief comes in from the US drug regulator for its active pharmaceutical ingredients (API) plant Miryalaguda.
Drug firm Alkem Laboratories today said it has received establishment inspection report (EIR) from the US health regulator on the closure of its inspection at its API facility at Ankaleshwar in Gujarat.
"The API is the first-of-its-kind, enabling developers to easily search and discover video content by providing information about entities, for example, dog, flower or human inside video content," said Chief Scientist Google Cloud (Artificial Intelligence and Machine Learning) Fei Fei Li at Cloud Next conference here.
Speaking from the sidelines of the India Pharmaceutical Forum 2017, Lupin's Managing Director Nilesh Gupta shared his outlook on Indian industry and API inspections.
There's no end in sight for the Indian pharmaceutical industry's struggles with domestic and foreign drug regulators. It's true that quite a few companies have received clean chits from regulators in the US, UK and Europe. However, at the same time, new issues have also been cropping up with disturbing frequency.
Drug firm Dr Reddy's Laboratories today said the US health regulator has made three observations after completing inspection of its Miryalaguda facility.
Glenmark Pharmaceuticals today said it has received four observations from the US health regulator for its Ankleshwar facility after inspection in December 2016.
The US business that constitutes close to half of Glenmark‘s business doubled to Rs.1230.8 crore led by new launches including generic version of Zetia - that has 180-day exclusivity.
Sun Pharmaceutical is working on a consolidation plan for its manufacturing units and as part of this plan is looking to sell its Ohm Labs manufacturing site based in New Jersey, reports CNBC-TV18.
The company told CNBC-TV18 that it has the capability to transfer active pharmaceutical ingredient (API) manufacturing to different units.
In an interview to CNBC-TV18, SP Tulsian of sptulsian.com shared his reading and outlook on the market as well as on specific stocks.
Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh & Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals & Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang Institutional Equities.
The company expects healthy growth going ahead, according to Ravi Kumar, ED and CFO of Laurus Labs, adding that its total debt post the IPO will stand at Rs 750 crore
Healthcare company Strides Shasun shares jumped more than 4 percent intraday Friday on acquisition of USFDA approved API (active pharmaceutical ingredients) facility in India.
The leading player in developing generic Active Pharmaceutical Ingredients (APIs) aims to utilise the net proceeds from the fresh issue towards pre-payment of term loans and general corporate purposes.